Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis

Journal of Viral Hepatitis

Volumn 15, Issue 4, 2008, Pages 246-249

  Biasiolo, A ^b   Chemello, L ^b   Quarta, S ^b   Cavalletto, L ^b   Bortolotti, F ^b   Caberlotto, C ^b   Beneduce, L ^c   Bernardinello, E ^b   Tono, N ^b,d   Fassina, G ^c   Gatta, A ^b   Pontisso, P ^a,b  

^a Department of Clinical and Experimental Medicine ^*  (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Xeptagen SpA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Chronic hepatitis outcome; Fibrosis progression; Serpin; Squamous cell carcinoma antigen

Indexed keywords

IMMUNOGLOBULIN M; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHRONIC HEPATITIS; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; VIROLOGY;

ADULT; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS, CHRONIC; HUMANS; IMMUNOGLOBULIN M; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SERPINS;

EID: 40149083902     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00935.x     Document Type: Article

References (22)

1. De Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003 39 (Suppl. 1 S3 S25.
2. Di Marco V, Lo Iacono O, Camma C et al. The long-term course of chronic hepatitis B. Hepatology 1999 30 :257 264.
3. Knodell RG, Ishak KG, Black WC et al. Formulation and application of numerical scoring system for assessing histological activity in asymtomatic chronic active hepatitis. Hepatology 1981 1 :431 435.
4. Ishak KG, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 :696 699.
5. Gunneson TJ, Menon KV, Weisner RH et al. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. Am J Gastroenterol 2002 97 : 1472 1475.
6. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000 133 : 665 675.
7. Sebastiani G, Alberti A. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006 21 : 3682 3694.
8. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003 38 : S136 S149.
9. Pontisso P, Quarta S, Caberlotto C et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006 119 : 735 740.
10. Beneduce L, Castaldi F, Marino M et al. Squamous cell carcinoma antigen-immunoglobulin M complex as novel biomarkers for hepatocellular carcinoma. Cancer 2005 103 : 2558 2565.
11. Spada E, Mele A, Ciaccozzi M et al. Changing epidemiology of parenterally transmitted viral hepatitis: results of the hepatitis surveillance system. Dig Liver Dis 2001 33 : 778 784.
12. Stroffolini T, Mele A, Tosti ME et al. The impact of hepatitis immunisation campaign on the incidence of the risk factors for hepatitis B in Italy. J Hepatol 2000 33 : 980 985.
13. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenetic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994 20 : 1442 1449.
14. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998 29 : 944 952.
15. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005 43 : 550 552.
16. Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004 36 : 646 654.
17. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003 97 : 3036 3043.
18. Friedenberg F, Pungpapong S, Zaeri N, Braitman LA. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab 2003 5 : 150 155.
19. Crespo J. The art of predicting fibrosis in hepatitis C. Rev Esp Enferm Dig 2006 98 : 153 160.
20. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004 127 : S35 S50.
21. Bolognesi M, Sacerdoti D, Merkel C, Bombonato G, Gatta A. Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound Med Biol 2001 27 : 901 907.
22. Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines? J Hepatol 2007 46 : 528 529.